The study, carried out in collaboration with scientists at the University Hospital of the Ludwig-Maximilians, University Munich, and collaborators at the Dana Farber Cancer Institute in Boston developed a test coined m7-FLIPI, which identifies follicular lymphoma patients at the highest risk for treatment failure.
Follicular lymphoma is a subtype of Non-Hodgkin Lymphoma and while effective treatments exist, approximately 20 per cent of patients respond poorly or not at all to current therapies.
Dr. Randy Gascoyne, distinguished scientist, BC Cancer Agency and scientific director of the Centre for Lymphoid Cancers along with PhD candidate and lymphoma fellow Dr. Robert Kridel, working closely with collaborators, have spent the past two years studying the genetic factors that cause treatment failure in follicular lymphoma.
“The work of Dr. Gascoyne, Dr. Kridel and other researchers has the ability to identify lifesaving solutions for patients living with follicular lymphoma,” said Health Minister Terry Lake. “Their findings are a great example of BC’s role as a leader in cancer treatment, prevention and the cutting edge research conducted through the BC Cancer Agency.”
“We set out to determine, at the time of diagnosis, which patients’ disease will have sustained responses after treatment and whether new genetic data could help inform which patients are at risk for developing progressive lymphoma so clinicians would be able to offer these high-risk patients more effective therapies,” said Dr. Gascoyne, senior co-author of the paper.
“The m7-FLIPI could be extremely significant for the medical community, changing the story for high-risk patients who are currently destined to not respond well to standard treatment.”
Identifying these patients up-front could be used to help determine candidates for testing novel therapies or enrollment on clinical trials.
The test was built upon an existing clinical risk factor test known as FLIPI, the Follicular Lymphoma International Prognostic Index. The team, directed by Dr. Oliver Weigert in Munich, developed improved prognostic algorithms and added the mutational status for seven genes known to be significant factors in the development and progression of follicular lymphoma.
m7-FLIPI is the first prognostic model in follicular lymphoma that accounts for clinical factors and genetic mutations. It is an effective tool that has the power to save and extend patients’ lives by steering clinicians toward more innovative and effective treatment options.
Looking ahead, m7-FLIPI would be utilized in a clinical setting to test all new follicular lymphoma patients at diagnosis in order to identify the roughly 25 per cent who harbor the most aggressive disease. Traditionally, these patients would receive standard therapy, which is currently prescribed to all follicular lymphoma patients and highly effective for many, yet not potent enough for up to a quarter of people diagnosed.
- Over 1,000 British Columbians will be diagnosed with a form of Non-Hodgkin Lymphoma this year, and approx. 300 of those will have follicular lymphoma.
- Follicular Lymphoma is one of two main subtypes of Non-Hodgkin Lymphoma.
- Approximately 25 per cent of follicular lymphoma patients will not respond well to standard therapy.
- The five-year survival rate for follicular lymphoma patients considered “low-risk” is approx. 91 per cent.
- The five-year survival rate for follicular lymphoma patients considered “high-risk” is approx. 53 per cent.
- m7-FLIPI combines clinical risk factor testing with mutational status for seven known mutations associated with follicular lymphoma.
- m7-FLIPI accurately identifies patients with disease that would be destined to experience early treatment failure.
- Prognostic testing can lead to more effective, life-saving treatment solutions from the onset.
- The BC Cancer Foundation has provided over $4 million to fund research in the BC Cancer Agency’s Centre for Lymphoid Cancers over the past five years.
Read the full news release